Call Us: 1.800.873.5297

By

Pradaxa® MDL Update (MDL 2385): $650 Million Settlement Reached in Federal Multidistrict Litigation

The Plaintiffs’ Steering Committee, appointed by The Honorable Chief Judge David R. Herndon to negotiate the settlement on behalf of all plaintiffs in the Pradaxa® MDL, and Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates) have negotiated a settlement program in the amount of $650 Million to resolve approximately 4,000 Pradaxa® claims. Roger C. Denton of Schlichter, […]

By

Manufacturer Wockhardt Recalls Generic Toprol XL Tablets

Bloomberg reports that the Mumbai-based manufacturer, Wockhardt Ltd., is recalling 109,744 bottles of its generic version (metoprolol succinate) of the heart pill Toprol XL. The FDA is starting to crack-down on manufacturers in its efforts to monitor the safety and quality of generics. According to an FDA report, the recall was issued as a result of […]

By

FDA Issues New Safety Announcement: Next-Day Impairment with Sleep Aid Lunesta®

On May 15, the U.S. Food and Drug Administration (FDA) issued a Safety Announcement warning that the insomnia drug Lunesta® (eszopiclone) can cause next-day impairment that can last more than 11 hours after receiving an evening dose. A recent study of Lunesta® found that the previously recommended dose of 3mg can cause impairment to driving […]

By

FDA Issues Proposed Orders to Reclassify Transvaginal Mesh to a High-Risk Device

On April 29, 2014, the FDA issued an immediate release notifying the public of its issuance of two proposed orders to address risks associated with surgical mesh for transvaginal repair of pelvic organ prolapse (POP). If these orders are finalized, these orders will reclassify transvaginal mesh products from a moderate-risk device (Class II) to a […]

By

Black Box Warning Regarding Increased Risk of Liver Failure and Death Added to Stavzor Product Label

In March 2014, the manufacturers of Stavzor added a Black Box Warning, which is the strongest type of warning, to the product label regarding the increased risk of liver failure and death. The Black Box Warning for Stavzor reads: “Hepatotoxicity, including fatalities, usually during first 6 months of treatment. Children under the age of two years […]

By

New Study Reports Potential Link between Viagra and Deadly Skin Cancer

A recent article published by JAMA Internal Medicine in April 2014 evaluated the association between sildenafil use and the risk of incident melanoma among men in the United States. The study concluded that “[s]ildenafil use may be associated with an increased risk of developing melanoma.” In particular, the researchers found that men who took sildenafil […]

By

FDA Issues New Safety Announcement: Increased Risk of Major GI Bleeding with Pradaxa Compared to Warfarin

On May 13, 2014, the FDA issued a Safety Announcement for Pradaxa regarding a recent study finding a higher risk of gastrointestinal (GI) bleeding with Pradaxa compared to warfarin. This information is in follow-up to the FDA’s Drug Safety Communication previously issued on November 2, 2012 regarding the risk of serious bleeding events with Pradaxa. […]

By

The Las Vegas Herald: Las Vegas Judge Denies Attempt to Remove Her from Actos Case

The Las Vegas Herald reports that Judge Kerry Earley will not remove herself from a civil case filed by two women against Takeda Pharmaceuticals, the manufacturer of Actos. The Honorable Judge Earley stated, “I absolutely see no evidence that there’s any appearance of impropriety by me.” The Honorable Judge Earley made her ruling after attorney […]

By

$830 Million Settlement Reached in Endo and American Medical Systems Transvaginal Mesh Litigation

Reuters reports that a settlement in the amount of $830 Million has been reached to resolve legal claims from women who allege to have been injured by transvaginal mesh devices manufactured by Endo and American Medical Systems. Endo (although not admitting liability or fault) released a statement indicating that the settlement agreement will provide compensation […]

By

ABC Detroit Reports: “Pradaxa is the Most Complained about Drug in the United States”

ABC Detroit reports that Pradaxa is the most complained about drug in the United States. Since its approval by the FDA in 2010, Pradaxa has been associated with 1,158 deaths and 12,494 serious injuries in the United States, according to Tom Moore , senior scientist for drug safety and policy at the Institute for Safe […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.